3rd Quarter - Report

BROWN RUDNICK LLP for AMNEAL PHARMACEUTICALS

A later version of this report replaces this one, so LegiList's totals use the current version instead. This page shows this version exactly as filed.

Firm
Client
Income
$30,000
Expenses
—

Versions of this report

Every filing the register holds for this firm, client and period, oldest first. The most recent one is the version LegiList counts.

Filing Filed Amount Counted
3rd Quarter - Report (this page) Oct 14, 2014 $30,000 Replaced
3rd Quarter - Amendment Oct 15, 2014 $30,000 Yes

What was lobbied

One issue area, each in the filer's own words, with who lobbied on it and where.

Pharmacy PHA

Supplemental Applications Proposing Labeling Changes for Approved Drugs and Biological Products Proposed Rule by FDA (RIN:0910-AG94); P.L. 110 -85 relating to Risk Evaluation and Mitigation Strategy programs.

LobbyistCovered position, as disclosed
CHRISTOPHER BOWLIN SPA, Sen John McCain (09-13)
LISA LAYMAN SPA, Sen Stabenow (05-07)
HENRY W MENN CoS, Sen Bob Graham (01-04)

Contacted: HOUSE OF REPRESENTATIVES; SENATE

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.